Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2022 | How the treatment and management of ALL changes with age

Emily Curran • 28 Sep 2022
SOHO 2022
Acute Lymphoblastic Leukemia Leukemia Antibodies Blinatumomab Inotuzumab ozogamicin

In this video, Emily Curran, MD, The University of Cincinnati, Cincinnati, OH, comments on how the treatment and management of acute lymphoblastic leukemia (ALL) changes with age. Dr Curran first explains the role of pediatric-based regimens in the treatment of ALL, and then goes on to highlight the importance of incorporating novel immunotherapies when treating older patients. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Emily Curran

The evolving role of inotuzumab ozogamicin in the treatment of pediatric & older patients with ALL
1:20
The evolving role of inotuzumab ozogamicin in the treatment of pediatric & older patients with ALL
Emily Curran • 28 Sep 2022
Treatment approaches to Ph-like ALL: challenges and future outlooks
2:04
Treatment approaches to Ph-like ALL: challenges and future outlooks
Emily Curran • 28 Sep 2022
The biology of Ph-like ALL and challenges in this disease subtype
1:16
The biology of Ph-like ALL and challenges in this disease subtype
Emily Curran • 28 Sep 2022

Related Videos

Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
4:04
Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
Anna Schuh • 16 Oct 2026
Understanding the CLL genome: current knowledge and remaining gaps
3:39
Understanding the CLL genome: current knowledge and remaining gaps
Anna Schuh • 16 Oct 2026
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
2:00
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
Alexey Danilov • 16 Oct 2026
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
3:39
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
Marta Coscia • 16 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals